GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Research & Development

Glenmark Pharmaceuticals (BOM:532296) Research & Development : ₹0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Glenmark Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0 Mil.


Glenmark Pharmaceuticals Research & Development Historical Data

The historical data trend for Glenmark Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Research & Development Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Glenmark Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Glenmark Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glenmark Pharmaceuticals  (BOM:532296) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Glenmark Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (BOM:532296) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines